skip to main content
Close Icon

This website uses cookies. By continuing to use this site, you agree to our use of cookies. To find out more visit our Cookie Policy page.

Global Search Configuration

Prostate Cancer Infographic Datamonitor Healthcare

Levers impacting access to prostate cancer treatment are very different in the US to the EU and the UK.

Download your complimentary prostate cancer infographic and discover:

Payer archetypes and trends in access

Least restrictive: US
Relatively unrestricted: France and Germany
Restrictive: Italian and Spanish regions
Most restrictive: UK
National Institute for Health and Care Excellence (NICE) applies arguably the most stringent cost-effectiveness analyses of any European nation

Levers impacting access to prostate cancer drugs in the US:

Insurers’ prior authorization criteria
Formulary tiering and patient co-pays
Oncology pathways

Levers impacting access to prostate cancer drugs in the five major EU markets:

National reimbursement decisions
Regional or local access criteria
Off-label prescribing controls
Budget limits
Risk-sharing agreements


Why Zytiga favored over Xtandi on Anthem’s oncology pathway?

What Medicare’s shift to value-based payment means

The rebates and risk-sharing agreements that will be valuable in non-metastatic CRPC


Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or email us your inquiry, so we can provide you the best possible customer service:

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: